• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

OMNY Health Enriches Real-World Data Ecosystem with Over 300 New Clinical Assessment Measures

by Fred Pennic 05/08/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
OMNY Health Launches GLP-1 Data Network to Advance Research

What You Should Know: 

– OMNY Health, a healthcare ecosystem provider for compliant real-world data insights at scale announced a significant expansion of its data network with the addition of more than 300 new clinical assessment measures. 

– These disease-specific measures, derived from clinical severity indicators, surveys, and questionnaires, are poised to offer a more granular and nuanced real-world view of patient health, thereby enhancing the ability to monitor disease progression and the impact of treatments across numerous medical specialties.

– The newly incorporated measures include critical information such as the Crohn’s Disease Activity Index (CDAI) and the Harvey Bradshaw index for Gastroenterology, as well as the Asthma Control Test and COPD Assessment Test (CAT) for Respiratory conditions. This expansion allows for deeper research and insights into areas including respiratory, cardiovascular, autoimmune, gastroenterology, neurology, and oncology.

Broadening Horizons: From Dermatology Focus to Pan-Therapeutic Value

This development marks a strategic move for OMNY Health, building upon its successful data strategy initially demonstrated in dermatology. The company is now leveraging its capabilities to extract and curate data from both structured and unstructured sources within its extensive pool of electronic health records (EHRs) to serve a wider range of healthcare research needs.

“For some time, OMNY Health has been seen as a dermatology data network, but with our network growth, we are moving beyond that and demonstrating the value of our solutions to the broader healthcare community,” said Dr. Mitesh Rao, CEO and Co-Founder of OMNY Health. “By leveling up research and making more information available across multiple specialties, OMNY Health enables teams to fill information gaps, accelerate research timelines, and make meaningful improvements to patient care.”

Deeper Insights for Enhanced Research and Care

OMNY Health’s expanded curated measures offering provides comprehensive data on critical aspects of patient health, including:

  • Longitudinal disease progression: Tracking flare-ups and treatment responses for chronic conditions such as asthma, COPD, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, lupus, epilepsy, and multiple sclerosis.
  • Real-world evidence: Offering insights on risk factors, medication adherence, and patient outcomes for conditions like heart failure and hypertension.
  • Post-surgical recovery: Enabling tracking of rehabilitation outcomes and treatment effectiveness across various conditions.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: real-world data (RWD)

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |